Adaptin Bio (APTN) EPS (Weighted Average and Diluted) (2023 - 2026)

Adaptin Bio's EPS (Weighted Average and Diluted) history runs 4 years deep, the most recent figure standing at $0.13 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) rose 30.0% year-over-year to $0.13; the TTM figure through Mar 2026 stood at -$0.41 (up 45.33% YoY), while the FY2025 annual figure was -$0.66, up 31.25% from the prior year.
• EPS (Weighted Average and Diluted) came in at $0.13 for Q1 2026 at Adaptin Bio, up from -$0.16 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.13 in Q1 2026 to a low of -$0.34 in Q3 2024.
• A 4-year average of -$0.1 and a median of -$0.1 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
• Across the five-year window, EPS (Weighted Average and Diluted) plunged 24900.0% in 2024 and jumped 200.0% in 2025, its largest moves.
• Adaptin Bio's EPS (Weighted Average and Diluted) stood at -$0.01 in 2023, then tumbled by 3614.29% to -$0.26 in 2024, then jumped by 38.46% to -$0.16 in 2025, then soared by 181.25% to $0.13 in 2026.
• According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered $0.13, -$0.16, and -$0.2 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison